Atenolol and bendrofluazide in hypertension

Area of Science:

• Pharmacology
• Cardiovascular Medicine

Background:

• Hypertension management requires effective and well-tolerated hypotensive agents.
• Beta-1 adrenergic receptor blockers offer a targeted approach to blood pressure control.

Purpose of the Study:

• To evaluate the efficacy and tolerability of atenolol, a selective beta-1 blocker, in hypertensive outpatients.
• To compare atenolol monotherapy with bendrofluazide and a combination therapy.

Main Methods:

• Double-blind, cross-over trial involving 24 hypertensive outpatients.
• Patients received placebo, atenolol (200mg/day, 400mg/day), atenolol 200mg/day plus bendrofluazide 5mg/day, and bendrofluazide 5mg/day alone in random sequence.
• Blood pressure and pulse rate were monitored throughout the study.

Main Results:

• Atenolol (both doses) significantly reduced blood pressure compared to bendrofluazide alone, except for standing systolic pressure.
• No significant difference in blood pressure or pulse rate was observed between the two atenolol doses.
• Combination therapy with atenolol and bendrofluazide resulted in further significant blood pressure reduction.
• Bendrofluazide showed a significant effect on patient weight.

Conclusions:

• Atenolol is an effective and well-tolerated hypotensive agent for managing hypertension.
• Its cardioselective nature and lack of certain side effects contribute to its favorable profile.
• Combination therapy can enhance blood pressure control in patients requiring more intensive treatment.